ACS Synthetic Biology· 2026Q1
Engineering Escherichia coli Nissle as a Safe Chassis for the Production of Therapeutic Peptides
- 0citations
- Q1SCImago
- 2026year
Short summary
Engineered probiotic E. coli Nissle (EcN) is rendered non-proliferative and capable of producing therapeutic peptides using a CRISPR-Cas12 system to shred its chromosome and a programmable expression circuit.
AI-generated from the title and abstract; the full text is not read.
Key points
- Engineered E. coli Nissle (EcN) to be a non-proliferative chassis for therapeutic peptide production.
- Utilized a CRISPR-Cas12 chromosome-shredding device to prevent bacterial propagation.
- Developed an AI-guided pipeline to predict anticancer cell-penetrating peptides (ACCPPs).
- Demonstrated proof-of-concept by producing an ACCPP in the engineered EcN and testing its anticancer activity in human cell culture.
AI-generated from the title and abstract; the full text is not read.
Abstract
Abstract Synthetic biology enables the installation of programable genetic functions in microorganisms, positioning them as versatile platforms for therapeutic applications. However, clinical translation requires chassis organisms that integrate safety, genetic stability, and precise control over the activity. Here, we present an innovative engineering framework for the probiotic Escherichia coli Nissle (EcN) that transforms EcN into a safe, efficient, and non-proliferative chassis for therapeutic production. The native EcN plasmids pM1 and pM2 were cured and repurposed to encode two functional modules: a CRISPR-Cas12 chromosome-shredding device that prevents bacterial propagation and a programable circuit for payload expression, thereby generating a non-proliferative therapeutic-producing system. To broaden the range of therapeutic payloads, we developed an artificial-intelligence-guided bioinformatic pipeline to predict anticancer cell-penetrating peptides (ACCPPs). As a proof of concept, a candidate identified through this workflow was produced in the engineered EcN chassis and evaluated in human cell culture for anticancer activity. Collectively, this strategy established a modular platform that integrates computational therapeutic discovery with engineered probiotic production, paving the way for the future development of safer microbial therapies and their clinical applications.
The authors' abstract, as published at the source. ACS Synthetic Biology, 2026 · DOI ↗
Continue with a free account
Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.
Continue free on the webSign in with Google or Apple; no card needed. You come back to this paper.
On your phone:
BiotechnologyBiochemistry, Genetics and Molecular Biology